An amino acid substitution in Fasciola hepatica P-glycoprotein from triclabendazole-resistant and triclabendazole-susceptible populations by Wilkinson, R. et al.
An amino acid substitution in Fasciola hepatica P-glycoprotein
from triclabendazole-resistant and triclabendazole-susceptible
populations
Wilkinson, R., Law, C. J., Hoey, E. M., Fairweather, I., Brennan, G. P., & Trudgett, A. (2012). An amino acid
substitution in Fasciola hepatica P-glycoprotein from triclabendazole-resistant and triclabendazole-susceptible
populations. Molecular and Biochemical Parasitology, 186(1), 69-72. DOI: 10.1016/j.molbiopara.2012.08.008
Published in:
Molecular and Biochemical Parasitology
Document Version:
Peer reviewed version
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
This is the author’s version of a work that was accepted for publication in Molecular and Biochemical Parasitology. Changes resulting from
the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be
reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was
subsequently published in Molecular and Biochemical Parasitology, VOL.186, ISSUE1, (01/11/2012)
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:16. Feb. 2017
Accepted Manuscript
Title: An amino acid substitution in Fasciola hepatica
P-glycoprotein from triclabendazole-resistant and
triclabendazole-susceptible populations
Authors: Richard Wilkinson, Christopher J Law, Elizabeth M








Please cite this article as: Wilkinson R, Law CJ, Hoey EM, Fairweather I, Brennan
GP, Trudgett A, An amino acid substitution in Fasciola hepatica P-glycoprotein from
triclabendazole-resistant and triclabendazole-susceptible populations, Molecular &
Biochemical Parasitology (2010), doi:10.1016/j.molbiopara.2012.08.008
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.









An amino acid substitution in Fasciola hepatica P-glycoprotein from triclabendazole-resistant and 
triclabendazole-susceptible populations.
Richard Wilkinsona, Christopher J Lawa, Elizabeth M Hoeya, Ian Fairweathera, Gerard P Brennana, Alan 
Trudgetta*
aSchool of Biological Sciences, The Queen’s University of Belfast
*Corresponding author: Alan Trudgett, School of Biological Sciences, The Queen’s University of Belfast, 
97, Lisburn Road, Belfast BT9 7BL, N.Ireland, UK.  Email a.trudgett@qub.ac.uk. Tel. +44 2890972125, Fax 
+44 2890975877.
Key Words: Fasciola hepatica; anthelmintic resistance; P-glycoprotein; SNP










Ribbon model of Liver Fluke P-glycoprotein with arginine substitution at residue 1144. 









 Triclabendazole-resistant liver flukes differ in their P-glycoprotein genes. 
 Triclabendazole-resistant flukes have greater allelic diversity. 
 Triclabendazole resistance correlates with a change in the P-glycoprotein X-loop. 
 This may provide the basis for a test for triclabendazole resistance. 
*Highlights










Control of fasciolosis is threatened by the development of anthelmintic resistance.  Enhanced 2 
triclabendazole (TCBZ) efflux by ABC transporters such as P-glycoprotein (Pgp) has been 3 
implicated in this process.  A putative full length cDNA coding for a Pgp expressed in adult 4 
Fasciola hepatica has been constructed and used to design a primer set capable of amplifying 5 
a region encoding part of the second nucleotide binding domain of Pgp when genomic DNA 6 
was used as a template.  Application of this primer set to genomic DNA from TCBZ-resistant 7 
and -susceptible field populations has shown a significant difference in the alleles present.  8 
Analysis of an allele occurring at a three-fold higher frequency in the “resistant” population 9 
revealed that it was characterised by a serine to arginine substitution at residue 1144.  10 
Homology modelling studies have been used to locate this site in the Pgp structure and hence 11 
assess its potential to modify functional activity.  12 
 13 
The common liver fluke (Fasciola hepatica) is a major cause of economic losses to 14 
agriculture in temperate regions, with cost estimated at US$2000 million per annum [1].  In 15 
the absence of an effective vaccine against the fluke control is achieved by chemotherapy.  16 
However, the effectiveness of the drug of choice, triclabendazole (TCBZ) - a benzimidazole 17 
derivative – is threatened by the development of resistant fluke populations; these have been 18 
reported from Australia, Europe and South America [reviewed in 2].  Work with TCBZ-19 
resistant isolates [3] has indicated that, in contrast to resistance to benzimidazoles in 20 
nematodes [4], TCBZ resistance is not associated with changes in the likely target molecule - 21 
tubulin [5].  TCBZ-resistant isolates have been shown to process TCBZ more rapidly and 22 
their resistant phenotype can be reversed, under in vitro conditions, by the co-administration 23 
of inhibitors of P-glycoprotein (Pgp) drug efflux pumps or drug detoxification pathways [2].  24 









F. hepatica is known to express a Pgp-like ABC transporter [6], although this protein has 25 
been reported to be predominately expressed in juvenile flukes, and, as such, generally will 26 
not be involved in TCBZ efflux from adult flukes established in the bile ducts of infected 27 
animals.  Recent publication of EST libraries for F. hepatica using mature flukes [7] 28 
(specifically contigs 1473, 14497, 10329 and 15817) in conjunction with work in our 29 
laboratory, has allowed the construction of a putative full length sequence encoding a F. 30 
hepatica Pgp expressed in adult flukes (supplementary material 1).  A primer set (forward 31 
primer 5’ ttggtgttgtatcgcaggaa 3’, reverse primer 5’ agccgaagtagcttcatcca 3’; enclosing 32 
residues 1090 to 1175) derived from the region coding for the second nucleotide binding 33 
domain of Pgp has been successfully applied to genomic DNA extracted from flukes from 34 
infra-populations in cattle raised on farms associated with either TCBZ susceptibility or 35 
resistance [8] and the amplicons sequenced.  (It should be noted that these are functional 36 
designations for the populations present on the two farms – the “resistant” populations 37 
contains up to 36% susceptible flukes and conversely, the “susceptible” population may 38 
contain a minority (<10%) of resistant flukes) [9].  The primers used were separated by 39 
255bp in the constructed coding sequence, but a product of approximately 830bp was 40 
routinely obtained.  Sequencing of these amplicons revealed that the increased size was due 41 
to the presence of a 569bp intron.  Characteristic 5’ (ATxGTGAG) and 3’ (CAGxGGC) 42 
splice sites were present at the beginning and end of the non-coding sequence (supplementary 43 
material 2).  Translation of the partial exons flanking the intron from a putatively TCBZ-44 
susceptible fluke gave a sequence that was identical to the translation of the relevant region 45 
of our full length F. hepatica sequence and had 77.4% identity with the second ABC 46 
transporter region of SMDR2, a Schistosoma mansoni putative Pgp (EMBL L26287), 47 
confirming that the amplicons produced using this primer set were derived from a gene 48 
coding for a liver fluke Pgp.  In order to compare the fluke populations present on the 49 









“susceptible” and “resistant” farms, genomic DNA from 10 flukes from each population was 50 
prepared and subjected to a PCR reaction using the second nucleotide binding site primers.  51 
After sequencing of the amplicons in both directions, an alignment was constructed and 52 
edited to give sequences of equal length.  The Phase 2.1 algorithm [10] incorporated in 53 
DnaSP [11] was used to reconstruct haplotypes where consistent evidence of heterozygosity 54 
(double peaks on sequencing chromatograms) was seen in order to allow the derivation of 55 
parameters of genetic diversity.  The susceptible population contained five haplotypes with a 56 
nucleotide diversity (π) of 0.00228.  Four of the ten flukes were heterozygous.  The resistant 57 
population contained seven haplotypes with a nucleotide diversity (π) of 0.00358 and three of 58 
these were heterozygous.  The presence of heterozygotes indicated that sexual reproduction 59 
with cross-fertilisation (with the possibility of recombination) had occurred in previous 60 
generations in each population.  A consideration of the mitochondrial haplotypes of the 61 
individual heterozygous flukes [8] revealed that there was no association between Pgp alleles 62 
and maternal lineage, again indicating cross-fertilisation.  There was significantly greater 63 
diversity (0.768 versus 0.442, P = 0.0002 by a one tailed t-test) in Pgp haplotypes seen in the 64 
fluke population from the farm exhibiting TCBZ resistance.  Ten unique haplotypes were 65 
observed when the resistant and susceptible populations were taken in toto.  The distribution 66 
of these haplotypes over the two populations and the Single Nucleotide Polymorphisms 67 
(SNPs) that define them are shown in Table 1.  Haplotype 1 was the most common, being 68 
present in all of the flukes from the susceptible population and eight of the flukes from the 69 
resistant population.  The remainder of the haplotypes were segregated between the 70 
susceptible and resistant populations.  As the two farms are approximately 100 km apart these 71 
differences could reflect geographical separation, however, with regard to TCBZ resistance, 72 
the mitochondrial haplotypes have been shown to be acting as neutral markers with the most 73 
common haplotype being present in approximately one third of the flukes from both farms 74 









[8].  We consider that the differences in frequency of alleles observed in this study are more 75 
likely to be due to different selective pressures having operated, directly or indirectly, on the 76 
expressed products of the Pgp genes present in the ancestors of the flukes presently at the two 77 
locations. 78 
There were 11 individual SNPs, of which 3 were transitions and the rest transversions.  Three 79 
of the changes were within the partial exons and also resulted in an amino acid change.  They 80 
were T28A, resulting in a valine to glutamic acid substitution at residue 1112; G54A, 81 
resulting in an alanine to threonine substitution at residue 1121; and T687G, resulting in a 82 
serine to arginine change at residue 1144.  The first of these changes (T28A) was seen in 3 83 
out of 10  TCBZ “susceptible” flukes and in 2 out of 10 TCBZ “resistant” flukes populations 84 
and the second (G54A) was exclusively (4 out of 10) in the TCBZ “susceptible” population.  85 
The third change (T687G giving S1144R) was seen more frequently in the TCBZ “resistant” 86 
population (3 out of 10 for the “resistant” flukes versus 1 out of 10 for the “susceptible” 87 
flukes) and was located four residues before the signature motif (LSGGQ) which interacts 88 
with adenosine triphosphate (ATP), suggesting that it may have functional significance. 89 
To allow us to investigate the potential significance of the S144R substitution we constructed 90 
a homology model of F. hepatica Pgp.  The amino acid sequence of the constructed F. 91 
hepatica Pgp sequence was used to search against the NCBI (National Center for 92 
Biotechnology Information) nonredundant protein sequence database with the programme 93 
PSI-BLAST [12] and identified mouse ABCB1, a multidrug transporter [13], as the closest 94 
relative of known structure.  The backbone co-ordinates for the core of the homology model 95 
were built based on the crystal structure of ABCB1a (PDB ID: 3G5U), in the inward-facing, 96 
nucleotide-free conformation as the template.  Alignment of the reconstructed F. hepatica 97 
and M. musculus primary sequences revealed a 41% identity between the two proteins.  The 98 
N-terminus (residues 1-33) of the template crystal structure was not resolved and electron 99 









density for the flexible linker region (residues 627-683) that connects the two halves of the 100 
transporter via nucleotide binding domain 1 (NBD1) and transmembrane domain 2 (TMD2) 101 
was missing [13].  Therefore, the N-terminus (residues 1-16) and linker region (residues 631 102 
to 674) were not built into our model of the TCBZ-resistant F. hepatica transporter. The final 103 
model corresponded to residues V17-H630 and V675-E1278 and consisted of 12 -helices 104 
arranged in two 6-helical bundle transmembrane domains (TMD1 and TMD2) and two 105 
cytoplasmic nucleotide-binding domains (NBD1 and NBD2). The protein takes on an overall 106 
V-shaped conformation in which NBD1 is associated with helices 1, 2, 3 and 6 of TMD1 and 107 
helices 10 and 11 of TMD2, and NBD2 is associated with helices 4 and 5 of TMD1 and 108 
helices 7, 8, 9 and 12 of TMD2 (Fig. 1).  The TMDs form two arms that straddle a substrate 109 
binding and translocation pore that is closed towards the extracellular side. The NBDs both 110 
contain the Walker A and B motifs and the conserved LSGGQ ABC transporter signature 111 
sequence, or C-motif. As shown in Figs. 1 and 2, the arginine residue (R1144) is located at 112 
the interface of NBD2 and its associated transmembrane domain, where it protrudes and 113 
introduces a positive charge into the space between the two domains. It is also positioned to 114 
participate in formation of the NBD dimer interface that occurs upon ATP binding. 115 
The stereochemical properties of the model as determined by PROCHECK revealed that 93% 116 
and 6.5% of residues were in the allowed and generously allowed regions, respectively, of the 117 
Ramachandran plot.  This compares favourably with the Ramachandran plot of the 118 
coordinates of the template structure in which 92.5% of residues were in the allowed regions, 119 
and 7.5% in the generously allowed.  The modelling of the F. hepatica Pgp demonstrated that 120 
residue 1144 is located in the region termed the X-loop, a part of the molecule which is 121 
thought to be involved in the cross-linking of the long intracellular loops (ICLs) in response 122 
to ATP binding and may transmit conformational changes to the ICLs [14].  Molecular 123 
dynamic simulations [15] have indicated that the regions of the molecule with which the X-124 









loop interacts potentially change during the cycle of nucleotide attachment and release, 125 
emphasising its probable importance in the functional activity of efflux pumps.  The S1144R 126 
substitution thus has the potential to modulate these conformational changes.  In a recent 127 
study of cattle ticks resistant to the macrocyclic lactone ivermectin, it was shown that there 128 
was an up-regulation of mRNA coding for an ABC transporter in resistant isolates [16].  This 129 
transcript also had an arginine in the position corresponding to residue 1144 in our assembled 130 
liver fluke sequence whereas two other cattle tick ABC transporters which had a glycine 131 
rather than arginine at this position were not up-regulated in the resistant tick isolates, 132 
supporting the hypothesis that this substitution may have functional consequences. 133 
The observation that the TCBZ-resistant population does not contain flukes homozygous for 134 
this allele may be due to the sample size; alternatively it may indicate that the S1144R 135 
substitution, whilst advantageous in the presence of TCBZ, is less appropriate for the other 136 
functions of Pgp required by the fluke.  It is intended to investigate this issue using F. 137 
hepatica Pgp expressed in vitro. 138 
In conclusion, the data presented in this study, although preliminary, support the suggestion 139 
that the development of TCBZ resistance in liver flukes is a multifactorial process involving 140 
changes in drug uptake, efflux and metabolism [2] and indicate that selection for variant Pgps 141 
may be part of this process.  The S1144R substitution is located in a region of the protein 142 
which is likely to be associated with its transporter functions.  If an enhanced ability to 143 
transport TCBZ and its metabolites is confirmed by expression studies with a multidrug 144 
efflux protein bearing this substitution this would strengthen its association with the 145 
development of TCBZ resistance in the liver fluke.  Analysis of isolates characterised with 146 
regard to TCBZ susceptibility [3] and field populations will be necessary to establish the 147 
importance of the S1144R substitution in the development of the TCBZ-resistant phenotype 148 
in locations other than the Netherlands.  If changes in this region of Pgp are widely associated 149 









with TCBZ resistance it may be possible to develop an allele-specific molecular test 150 
analogous to that used for nematodes [17] for potentially TCBZ-resistant populations based 151 
upon genomic DNA extracted from fluke eggs.  These are a source of F. hepatica genomic 152 
DNA readily available for epidemiological surveys. 153 
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Legends to figures 215 
Fig 1. Homology model of the F. hepatica P-glycoprotein – front and rear views.  The 216 
position of residue R1144 (represented as a red space-fill) is indicated by the circle and is 217 
located at the interface of NBD2 and its associated transmembrane domain, TM4.  TM, 218 
transmembrane domain; NBD, nucleotide binding domain.  Homology modelling was 219 
performed using MolIDE 1.7 [18].  PSIPRED was used to perform initial secondary structure 220 
prediction of the target, and the target-template sequence alignment was adjusted manually 221 
using the predicted secondary structure of the target and the experimental secondary structure 222 
of the template as a guide for gap placement. During building of the backbone core of the 223 
model, only those side-chains that are conserved between target and template were preserved. 224 
The remaining, non-conserved side chains were built onto the backbone with SCWRL4 [19], 225 
and loops modelled with Loopy [20].  The model was visualised using The PyMOL 226 
Molecular Graphics System, Version 1.3 (Schrödinger, LLC).  227 
 228 
Fig 2. Close-up of the NBD2 region of the homology model showing residue 1144.  A – 229 
modelled with arginine as residue 1144, B – modelled with serine as residue 1144. 230 









Haplotype Single Nucleotide Polymorphisms Number (Resistant/ Susceptible) Change in Protein 
1 - 23 (Resistant and Susceptible) - 
2 A564G, T687G 1 (Susceptible) S1144R 
3 T28A, G54A, G181T, T267G, G323T, A564G, 1 (Susceptible) V1112E, A1121T, 
4 T28A, G54A, C60T, 2 (Susceptible) V1112E, A1121T 
5 G54A 1 (Susceptible) A1121T 
6 G181T, T267G, A617T 1 (Resistant)  
7 G181T, T267G, G323T, A617T, T687G 2 (Resistant) S1144R 
8 T267G, A617T, 6 (Resistant)  
9 T28A, G181T, T307A 1 (Resistant) V1112E 
10 G20C, T28A, T307A, T687G 1 (Resistant) V1112E, S1144R 
 
Table 2 Constructed haplotypes, their distribution in the two populations and non-synonymous changes in exons. 
Table(s)
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